ZEAL Zealand Pharma A/S

14.51
-0.11  -1%
Previous Close 14.62
Open 14.52
Price To Book 2.38
Market Cap 445784984
Shares 30,722,604
Volume 2,314
Short Ratio
Av. Daily Volume 4,702

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated September 2018.
Dasiglucagon
Congenital hyperinsulinism
Phase 3 data released September 18, 2018. Endpoints met.
Dasiglucagon
Severe hypoglycemia in diabetes
Phase 3 trial met primary endpoint - March 2018.
Dasiglucagon
Severe hypoglycemia in diabetes
Phase 3 trial initiation announced October 4, 2018.
Glepaglutide
Short bowel syndrome
Phase 3 data 1H 2019.
Dasiglucagon
Severe hypoglycemia in diabetes - children
Phase 2b trial to be completed 1H 2019.
Dasiglucagon dual-hormone pump therapy
Diabetes